Northland Capital partners view on Evgen Pharma PLC: Evgen is positioning itself to become the world’s unique provider of sulforaphane and sulforaphane-like pharmaceuticals. The group is already a first-mover in
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has acquired exclusive worldwide licensing rights to a wide range
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its interim results for the six months ended
Evgen Pharma’s Dr Stephen Franklin discusses Evgen’s unusual start, floating a second company and finding his way from PhD Biochemist to entrepreneur in this exclusive interview with DirectorsTalk
Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin discusses the unusual start to Evgen Pharma, what it’s like to float a second company and how Stephen found his way into
Evgen Pharma’s Dr Stephen Franklin discusses their successful IPO, their previous attempt and the broccoli angle in this exclusive interview with DirectorsTalk
Evgen Pharma CEO Dr Stephen Franklin discusses the broccoli angle, the events surrounding last years IPO and the successful IPO last month.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
